#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2018 - 5

Lung cancer

Czech version

Authors: Jana Skřičková;  Bohdan Kadlec;  Ondřej Venclíček;  Zdeněk Merta
Authors‘ workplace: Klinika nemocí plicních a TBC LF MU a FN Brno
Published in: Čas. Lék. čes. 2018; 157: 226-236
Category: Review Article

Overview

Lung cancer is one of the most common cancers worldwide. Approximately 85 % of lung cancers are non-small cell lung cancers while 15 % are small cell lung cancers. Histologically, following subtypes of non-small cell cancer are distinguished: adenocarcinoma (38.5 % of all lung cancers), squamous cell carcinoma (20 %) and large cell carcinoma (3 %). Over recent years, the incidence of adenocarcinoma has been increasing. Squamous cell carcinoma is more commonly associated with smoking while adenocarcinoma is the most common histological type in non-smokers.

The treatment of non-small cell lung cancer is decided according to clinical stage, morphological diagnosis, and the performance status of the patient. Early-stage patients are typically indicated for surgery. In some cases, adjuvant therapy is indicated. In locally advanced and metastatic stages, chemotherapy, biological treatment, and, recently, immunotherapy is indicated. Radiotherapy should also be considered for locally advanced disease. In small-cell lung cancer, the combination of etoposide and cisplatin or etoposide and carboplatin is still considered standard chemotherapy. Radiotherapy is an integral part of treatment of either type of lung cancer.

Keywords:

lung cancer, non-small cell lung cancer, small cell lung cancer, chemotherapy, biological therapy, radiotherapy, immunotherapy

Sources
  1. Dušek L, Malúšková D, Mužík J et al. Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v České republice. Onkologická Revue 2016; 8, Speciál (Současné trendy v léčbě karcinomu plic): 7–1
  2. Moulis M. Morfologická diagnostika karcinomu plic. In: Skřičková J. Kolek V. a kol. Základy moderní pneumoonkologie ( vyd.). Maxdorf, Praha, 2017.
  3. Giroux DJ, Rami-Porta R, Chansky K et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 2009; 4: 679–68
  4. Skřičková J, Kolek V a kol. Základy moderní pneumoonkologie (2. vyd.). Maxdorf, Praha, 2017.
  5. Skřičková J, Venclíček O, Kadlec B a kol. Nemalobuněčný karcinom plic. Postgraduální medicína 2016; 18, Příloha 1 (Pneumoonkologie): 21–27.
  6. Sculier JP, Moro-Sibilot D. First-and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009; 33(4): 915–930.
  7. Ginsberg RJ. Lung Cancer. BC Decker Hamilton, London, 2002.
  8. Pallis AG, Gridelli C, Wedding U et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014; 25: 1270–1283.
  9. Lien K, Georgsdottir S, Sivanathan L et al. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 2013; 49: 3387–3395.
  10. Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957.
  11. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132.
  12. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–246.
  13. Yang JCH, Schuler MH, Yamamoto N et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012; 30(18 Suppl.): LBA7500.
  14. Mok TS, Wu YI, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.
  15. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227–1234.
  16. Reck M. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. ASCO Annual Meeting 2013. J Clin Oncol 2013; 31(Suppl.): abstr. #LBA8011.
  17. Hanna NH. LUME-Lung 2: a multicentre, randomized, double-blind, phase III study of nintedanib plus pemetrexed vs. placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. American Society of Clinical Oncology, Chicago, 2013 Jun 2. J Clin Oncol 2013; 31(Suppl.): abstr. #8034.
  18. Perol M, Ciuleanu TE, Arrieta O et al. REVEL: a randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol 2014; 32: 5(suppl.): abstr. #LBA8006.
  19. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011; 17: 2081–2086.
  20. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189–1197.
  21. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247–255.
  22. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non-small cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer 2010; 11: 228–237.
  23. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275–5283.
  24. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175: 7746–7754.
  25. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220–5227.
  26. Kawai O, Ishii G, Kubota K et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 2008; 113: 1387–1395.
  27. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J Clin Oncol 2012; 30: 2046–2055.
  28. Spigel DR, Reckamp KL, Rizvi N et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33(Suppl.): abstr. 8009.
  29. Hossein Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.
  30. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833.
  31. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
  32. Garassino MC, Rizvi N, Besse B et al. Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients: updated ORR, PFS and OS data from the BIRCH study. World Conference on Lung Cancer 2016 Dec 5; Abstract OA03.02.
  33. Schmerling RA. Toxicity of checkpoint inhibitors. Chin Clin Oncol 2014; 3: 31.
  34. Lakomý R, Poprach A. Nežádoucí účinky moderní imunoterapie a jejich řešení v klinické praxi. Klinická onkologie 2015; 28(Suppl 4): 4S103–4S114.
  35. Vallières E, Shepherd FA, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4: 1049–1059.
  36. Almquist D, Mosalpuria K, Ganti AK. Multimodality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2016; 12: 111–117.
  37. Corso ChD, Rutter ChE, Park HS et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol 2015; 33: 4240–4246.
  38. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. Dostupné na: www.nccn.org
  39. Niho S, Kubota K, Yoh K et al. Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. J Thorac Oncol 2008; 3: 723–727.
  40. Hanna N, Bunn PA, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038–2043.
  41. Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 2008; 6: 323–331.
  42. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009; 115: 842–850.
  43. Nawal L, Islam KMM, Deviany PE et al. Survival trends of small cell lung cancer (SCLC) in the United States: a SEER database analysis. J Thorac Oncol 2015; 10(9, Suppl. 2): S402.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Idiopathic pulmonary fibrosis: Does the time for change of diagnostic and therapeutic recommendations come?
Treatment of tobacco dependence as a standard part of oncology care
Alcohol as an issue of the public health in the Czech Republic: facts and context
The origin and development of fat droplet and its role in health and illness
Aulus Cornelius Celsus and a regimen
Article was published in

Journal of Czech Physicians

Issue 5
2018 Issue 5
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#